However, currently, no medications are approved for the treatment of obesity in children younger than 12, with the exception of setmelanotide, a melanocortin-4 receptor agonist approved for select cases of monogenic obesity and Bardet-Biedl syndrome in children aged 2 and older [7, 8]. The gene discussed is MC4R; the disease is obesity due to melanocortin 4 receptor deficiency.